105 related articles for article (PubMed ID: 1586622)
1. Antitumor activity of 1,4-bis (2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis Maleate) in M5076 and its subline resistant to cyclophosphamide M5/CTX.
Tagliabue G; Filippeschi S; Hendricks H; D'Incalci M
Ann Oncol; 1992 Mar; 3(3):233-6. PubMed ID: 1586622
[TBL] [Abstract][Full Text] [Related]
2. DNA damage and sequence specificity of DNA binding of the new anti-cancer agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate).
Broggini M; Hartley JA; Mattes WB; Ponti M; Kohn KW; D'Incalci M
Br J Cancer; 1990 Feb; 61(2):285-9. PubMed ID: 2393411
[TBL] [Abstract][Full Text] [Related]
3. Ovarian reticular cell sarcoma of the mouse (M5076) made resistant to cyclophosphamide.
D'Incalci M; Torti L; Damia G; Erba E; Morasca L; Garattini S
Cancer Res; 1983 Dec; 43(12 Pt 1):5674-80. PubMed ID: 6357429
[TBL] [Abstract][Full Text] [Related]
4. Frequent administration of Dabis Maleate, a phase I study.
Verweij J; Planting AS; de Boer M; van der Burg ME; Stoter G
Ann Oncol; 1992 Mar; 3(3):241-2. PubMed ID: 1586625
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a novel mouse reticular cell sarcoma M5076 subline resistant to cisplatin.
Ferrari A; Damia G; Erba E; Rossi C; Mandelli R; D'Incalci M
Int J Cancer; 1989 Jun; 43(6):1091-7. PubMed ID: 2659542
[TBL] [Abstract][Full Text] [Related]
6. Antitumoral activity of the oxazaphosphorine derivative, mafosfamide-cyclohexylamine salt (ASTA 7557) on a murine ovarian reticular cell sarcoma and its subline resistant to cyclophosphamide.
Colombo T; Paolini A; Finazzi M; Scanziani E; Mandelli G; Donelli MG
Tumori; 1986 Dec; 72(6):637-42. PubMed ID: 3544404
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of DABIS maleate given once every 3 weeks.
van der Burg ME; Planting AS; Stoter G; McDaniel C; Vecht CJ; Verweij J
Eur J Cancer; 1991; 27(12):1635-7. PubMed ID: 1782074
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo characterisation of low-resistant mouse reticulosarcoma (M5076) sublines obtained after pulse and continuous exposure to cisplatin.
Belvedere G; Imperatori L; Damia G; Tagliabue G; Meijer C; de Vries EG; D'Incalci M
Eur J Cancer; 1996 Oct; 32A(11):2011-8. PubMed ID: 8943689
[TBL] [Abstract][Full Text] [Related]
9. Effects of a prospective antitumor agent, 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane diperchlorate, on cultured mammalian cells.
Traganos F; Darzynkiewicz Z; Bueti C; Melamed MR
Cancer Invest; 1984; 2(1):1-13. PubMed ID: 6584191
[TBL] [Abstract][Full Text] [Related]
10. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
11. Antineoplastic agents LXIV: 1,4-Bis(2'-chloroethyl)-1,4-diazabicyclo[2.2.1]heptane dihydrogen dimaleate.
Pettit GR; Gieschen DP; Pettit WE
J Pharm Sci; 1979 Dec; 68(12):1539-42. PubMed ID: 529047
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of the novel nitrosourea S10036 in rodent tumors.
Filippeschi S; Colombo T; Bassani D; De Francesco L; Arioli P; D'Incalci M; Bartosek I; Guaitani A
Anticancer Res; 1988; 8(6):1351-4. PubMed ID: 3064716
[TBL] [Abstract][Full Text] [Related]
13. Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin.
Damia G; Tagliabue G; Zucchetti M; Davoli E; Sessa C; Cavalli F; D'Incalci M
Cancer Chemother Pharmacol; 1992; 30(6):459-64. PubMed ID: 1394802
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of FCE 26644 a new growth-factor complexing molecule.
Sola F; Farao M; Pesenti E; Marsiglio A; Mongelli N; Grandi M
Cancer Chemother Pharmacol; 1995; 36(3):217-22. PubMed ID: 7781141
[TBL] [Abstract][Full Text] [Related]
15. Schedule-dependent effectiveness of ADM and multiple cycles of DDP on a murine reticulum sarcoma.
Leonetti C; Zupi G; Calabresi F; Greco C
Anticancer Res; 1990; 10(1):45-8. PubMed ID: 2185688
[TBL] [Abstract][Full Text] [Related]
16. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of norcantharidin on K562 human myeloid leukemia cells in vitro.
Yi SN; Wass J; Vincent P; Iland H
Leuk Res; 1991; 15(10):883-6. PubMed ID: 1921448
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide-resistant Yoshida ascites tumor cells and their cross resistance to some alkylating agents.
Gerhartz HH; Liss E; Schmidt H
J Cancer Res Clin Oncol; 1979 Jul; 94(3):257-63. PubMed ID: 479265
[TBL] [Abstract][Full Text] [Related]
19. Combination of the new minor groove alkylator tallimustine and melphalan.
Tagliabue G; Filippini C; Ubezio P; D'Incalci M
Eur J Cancer; 1997 Feb; 33(2):284-7. PubMed ID: 9135501
[TBL] [Abstract][Full Text] [Related]
20. Cis-diamminedichloroplatinum sensitivity of murine reticulum sarcoma cells in primary culture and after in vitro passages.
Balconi G; Damia G; Morali F; Marzola M; Tagliabue G; Erba E; D'Incalci M
In Vitro Cell Dev Biol Anim; 1993 Aug; 29A(8):617-9. PubMed ID: 8376309
[No Abstract] [Full Text] [Related]
[Next] [New Search]
